D Pharm Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
D Pharm Ltd Announces Retirement of Chairman, Mr. Ruben Krupik; Appoints Mr. Aharon Schwartz as Replacement-Complete Story
D Pharm Ltd announced that its Chairman, Mr. Ruben Krupik, has retired from the Company effective August 13, 2012. The Company has appointed Mr. Aharon Schwartz as its new Chairman, with effect from August 13, 2012.
Latest Developments for D Pharm Ltd
Latest Key Developments in Biotechnology
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Share this
- Digg this